Waystar Holding Corp. (NASDAQ:WAY) is one of the best digital health stocks to buy now.
On October 30, 2025, following the company’s third-quarter earnings, Mizuho Securities lifted its target from $48 to $50 and reiterated an Outperform rating, citing strong demand for Waystar’s revenue cycle management solutions. The firm highlighted that adoption of AI-driven claims denial tools was a key contributor to the company’s above-consensus performance.
Waystar Holding Corp. (NASDAQ:WAY) released their Q3 report on October 29, 2025. Double-digit growth came from steady transaction volume, expanding client adoption, and early Iodine Software cross-sell, which lifted revenue 12% to $268.7M and kept adjusted EBITDA strong at $112.7M with a 42% margin. Cost discipline and scale did the rest, converting more of each dollar into profit and pushing net income to $30.6M. Management raised full-year targets, signaling confidence that the Iodine integration and pipeline can carry momentum into 2026: revenue to $1.085–$1.093B and adjusted EBITDA to $451–$455M.
Waystar Holding Corp. (NASDAQ:WAY) is a healthcare payments and revenue cycle technology provider. Its cloud-based software is used by hospitals, physician groups, and other care organizations to manage claims processing, billing, prior authorizations, and patient financial interactions.
While we acknowledge the potential of WAY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None.
